Israel's Ministry of Health has granted an approval for Brainsway Deep Transcranial Magnetic Stimulation (TMS) device to market and sell the device to four medical centers to treat neurological and psychopathological disorders.
Brainsway TMS systems is a noninvasive devices which treats major depression, bipolar disorder and negative symptoms and cognitive impairment in schizophrenic patients.
The company said any brain-related disorder that is associated with pathological activity of specific brain sites may be treated by this method.
Brainsway CEO Uzi Sofer said they are now working to update indications with the Israeli Ministry of Health to bring them more in line with the approvals that they’ve already received in Europe.